IN8bio Reports Q1 2025 Financial Results Amid Cost-Cutting Measures

In8bio, Inc. ( (INAB) ) has released its Q1 earnings. Here is a breakdown of the information In8bio, Inc. presented to its investors.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for treating solid and liquid tumors, with its lead product candidate, INB-100, undergoing a Phase 1 clinical trial for acute myeloid leukemia. In its latest earnings report for the quarter ending March 31, 2025, IN8bio reported a net loss of $5.6 million, a decrease from the $8.6 million loss in the same period last year, reflecting cost-cutting measures including a significant workforce reduction. The company’s operating expenses also decreased to $5.7 million from $8.6 million, driven by reduced research and development and administrative costs. Despite these efforts, IN8bio’s cash reserves of $11.9 million are not expected to cover its operating expenses for the next 12 months, indicating a need for additional capital through equity or debt offerings. Looking ahead, IN8bio remains focused on advancing its clinical programs and exploring strategic collaborations to support its financial and operational goals.